tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Spada M et al. | Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. | 2006 | Am. J. Transplant. | pmid:16771811 |
| Frassetto LA et al. | Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. | 2007 | Am. J. Transplant. | pmid:17949460 |
| Saliba F et al. | Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial. | 2017 | Am. J. Transplant. | pmid:28133906 |
| Levitsky J and Feng S | Sirolimus and mTOR inhibitors in liver transplantation: the wheel has come full circle. | 2014 | Am. J. Transplant. | pmid:24620373 |
| de Fijter JW et al. | Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. | 2017 | Am. J. Transplant. | pmid:28027625 |
| Krämer BK et al. | Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. | 2003 | Am. J. Transplant. | pmid:12859533 |
| Ciancio G et al. | The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients. | 2003 | Am. J. Transplant. | pmid:12859538 |
| Trofe-Clark J et al. | Immunosuppression, generic drugs and the FDA. | 2012 | Am. J. Transplant. | pmid:22176626 |
| Latran M | Response to Klintmalm on the use of generic immunosuppression. | 2012 | Am. J. Transplant. | pmid:22176636 |
| Asrani SK et al. | De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. | 2014 | Am. J. Transplant. | pmid:24456026 |
| Song L et al. | ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys. | 2017 | Am. J. Transplant. | pmid:27598231 |
| Krenzien F et al. | Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus. | 2017 | Am. J. Transplant. | pmid:27754593 |
| Saikali JA et al. | Sirolimus may promote thrombotic microangiopathy. | 2003 | Am. J. Transplant. | pmid:12603218 |
| Ekberg H et al. | Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. | 2009 | Am. J. Transplant. | pmid:19563339 |
| Flechner SM et al. | Allotransplantation of cryopreserved parathyroid tissue for severe hypocalcemia in a renal transplant recipient. | 2010 | Am. J. Transplant. | pmid:20883540 |
| Koefoed-Nielsen PB et al. | Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. | 2002 | Am. J. Transplant. | pmid:12099520 |
| BenÃtez CE et al. | ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. | 2010 | Am. J. Transplant. | pmid:20883560 |
| Alloway RR et al. | A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. | 2012 | Am. J. Transplant. | pmid:22759200 |
| Madariaga ML et al. | Kidney-induced cardiac allograft tolerance in miniature swine is dependent on MHC-matching of donor cardiac and renal parenchyma. | 2015 | Am. J. Transplant. | pmid:25824550 |
| Pescovitz MD et al. | A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19663892 |
| Vanrenterghem Y et al. | Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. | 2005 | Am. J. Transplant. | pmid:15636615 |
| Sindhi R et al. | Enhanced donor-specific alloreactivity occurs independently of immunosuppression in children with early liver rejection. | 2005 | Am. J. Transplant. | pmid:15636616 |
| Shergill AK et al. | Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. | 2005 | Am. J. Transplant. | pmid:15636619 |
| Vincenti F et al. | Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. | 2007 | Am. J. Transplant. | pmid:17359512 |
| Cendales L et al. | Tacrolimus to Belatacept Conversion Following Hand Transplantation: A Case Report. | 2015 | Am. J. Transplant. | pmid:25773260 |
| Padiyar A et al. | Clinical predictors of proteinuria after conversion to sirolimus in kidney transplant recipients. | 2010 | Am. J. Transplant. | pmid:20055793 |
| Jaksch P et al. | Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study. | 2014 | Am. J. Transplant. | pmid:25039364 |
| Tan HP et al. | Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. | 2009 | Am. J. Transplant. | pmid:19120078 |
| Ashman N et al. | Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. | 2009 | Am. J. Transplant. | pmid:19120084 |
| Bhorade SM et al. | Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation. | 2003 | Am. J. Transplant. | pmid:14629288 |
| Pondrom S | The AJT report. | 2008 | Am. J. Transplant. | pmid:18324976 |
| Okabayashi T et al. | Mobilization of host stem cells enables long-term liver transplant acceptance in a strongly rejecting rat strain combination. | 2011 | Am. J. Transplant. | pmid:21883903 |
| Hellemons ME et al. | Former smoking is a risk factor for chronic kidney disease after lung transplantation. | 2011 | Am. J. Transplant. | pmid:21883906 |
| Maes BD et al. | Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. | 2002 | Am. J. Transplant. | pmid:12484345 |
| Pallet N et al. | Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations. | 2015 | Am. J. Transplant. | pmid:25588704 |
| Schussler T et al. | Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant. | 2004 | Am. J. Transplant. | pmid:15268744 |
| Min SI et al. | Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. | 2013 | Am. J. Transplant. | pmid:23734831 |
| Teuteberg JJ et al. | Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. | 2010 | Am. J. Transplant. | pmid:19889126 |
| Haufroid V et al. | CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. | 2006 | Am. J. Transplant. | pmid:17049058 |
| Shapiro R et al. | Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation. | 2007 | Am. J. Transplant. | pmid:17908272 |
| Turgut F and Akcay A | Renal function estimation in cirrhosis. | 2009 | Am. J. Transplant. | pmid:19519814 |
| Irish WD et al. | Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. | 2011 | Am. J. Transplant. | pmid:21564522 |
| Tricot L et al. | Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. | 2009 | Am. J. Transplant. | pmid:19519819 |
| Friman S et al. | Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. | 2011 | Am. J. Transplant. | pmid:21564523 |
| Kofler S et al. | Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. | 2009 | Am. J. Transplant. | pmid:19519820 |
| Margreiter R et al. | Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. | 2008 | Am. J. Transplant. | pmid:18510632 |
| Mandelbrot DA et al. | Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus. | 2015 | Am. J. Transplant. | pmid:26176342 |
| Finn L et al. | Epstein-Barr virus infections in children after transplantation of the small intestine. | 1998 | Am. J. Surg. Pathol. | pmid:9500771 |
| Randhawa PS et al. | The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. | 1993 | Am. J. Surg. Pathol. | pmid:7680544 |
| Minervini MI et al. | Acute renal allograft rejection with severe tubulitis (Banff 1997 grade IB). | 2000 | Am. J. Surg. Pathol. | pmid:10757402 |